A data analytics company that specialises in the area of healthcare and medicine is announcing plans today for the launch of the world's first diagnostic network for precision medicine.
The network is the culmination of a €26m investment and a decade of research and development by Diaceutics.
The company is listed on London's Alternative Investment Market and has offices in Belfast and Dundalk.
The Diagnostic Network, or DXRX, is described as the world's biggest diagnostic data repository with more than 2,500 labs working together to enable practitioners to collaborate and source precision medicine for patients.
Precision medicine is an emerging area of disease treatment and prevention that takes into account variability in genetics, the environment and lifestyle for each individual.
It is understood to be particularly effective in the treatment of certain types of cancer.
The network enables participating laboratories to work together to develop a pool of testing data and giving them access to the latest developments in precision medicine.
"Our experience of working on every precision medicine currently on the market puts Diaceutics in a unique position to advance a significantly better industry model and deliver significant new value for all stakeholders in precision medicine," Ryan Keeling, Diaceutics' chief innovation officer said.
The network is expected to be fully operational and accessible to pharmaceutical clients towards the end of the year.
